SCHEMBL5832098

SCHEMBL5832098

COc1cc(-c2nc3ccccc3o2)ccc1-c1ccc(Cl)cn1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.61
PTGS2 P35354 3/20 0.54
TP53 P04637 5/20 0.50
PTPN2 P17706 2/20 0.50
PTPN1 P18031 2/20 0.50
PTPN5 P54829 2/20 0.50
ALDH1A1 P00352 5/20 0.48
NPSR1 Q6W5P4 2/20 0.48
HTT P42858 1/20 0.48
HPSE Q9Y251 1/20 0.45
ALOX5 P09917 1/20 0.45
KDM4E B2RXH2 4/20 0.44
HSD17B10 Q99714 3/20 0.44
HPGD P15428 3/20 0.44
RAB9A P51151 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MAPT P10636 4/20 0.43
USP2 O75604 2/20 0.43
TSHR P16473 2/20 0.43
HCRTR1 O43613 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5832164 0.88 NPC1 (0.62) NPC1PTGS2TP53PTPN2PTPN1
SCHEMBL5832587 0.87 NPC1 (0.61) NPC1PTGS2TP53PTPN2PTPN1
SCHEMBL5832552 0.85 NPC1 (0.59) NPC1PTGS2TP53PTPN2PTPN1
Hydrochloric Acid SCHEMBL5831703 0.83 NPC1 (0.65) NPC1PTGS2TP53PTPN2PTPN1
SCHEMBL12956189 0.82 NPC1 (0.79) NPC1PTGS2TP53PTPN2PTPN1
SCHEMBL5832537 0.82 NPC1 (0.64) NPC1PTGS2TP53PTPN2PTPN1
SCHEMBL5832494 0.82 NPC1 (0.67) NPC1PTGS2TP53PTPN2PTPN1
Hydrochloric Acid SCHEMBL5832846 0.81 NPC1 (0.65) NPC1PTGS2TP53PTPN2PTPN1
SCHEMBL24155569 0.81 NPC1 (0.60) NPC1PTGS2TP53PTPN2PTPN1
SCHEMBL5832820 0.80 NPC1 (0.53) NPC1PTGS2TP53ALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7087601-B2 Metabotropic glutamate receptor-5 modulators MERCK & CO., INC. (US) 2006-08-08 US disclosed
EP-1453815-A4 METABOTROPIC GLUTAMATE RECEPTOR-5 MODULATORS MERCK & CO INC (US) 2005-04-06 EP disclosed
US-20050065340-A1 Metabotropic glutamate receptor-5 modulators MERCK SHARP & DOHME CORP. 2005-03-24 US disclosed
EP-1453815-A1 METABOTROPIC GLUTAMATE RECEPTOR-5 MODULATORS Merck & Co., Inc. (US) 2004-09-08 EP disclosed
WO-2004030637-A2 TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE MERCK & CO., INC. (US) 2004-04-15 WO disclosed
WO-2003048137-A1 METABOTROPIC GLUTAMATE RECEPTOR-5 MODULATORS MERCK & CO., INC. (US) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065340-A1 Metabotropic glutamate receptor-5 modulators GRM5, GRIK5, GRM1 NPC1 3080/4885PTGS2 1019/4885TP53 4829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.